Free tool
FAERS Monitor: Andembry
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761367 or its brand name (Andembry, Garadacimab-Gxii). Reports on generic versions are filed under their own applications.
Reports
767
Serious
597
78% of reports
Hospitalization
193
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hereditary angioedema498
- drug ineffective93
- product dose omission issue83
- stress68
- product use issue60
- weight decreased48
- fatigue43
- therapy interrupted43
- hospitalisation42
- insurance issue42
- weight increased42
- pain38
- off label use34
- headache32
- illness32
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 25 |
| 2025 | 223 |
| 2026 | 507 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,392 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hereditary angioedemaSignal | 498 | 1334.4 | 1262.4 | 631,826 |
| insurance issueSignal | 42 | 75.5 | 56.3 | 3,008 |
| stressSignal | 68 | 25.9 | 20.6 | 1,606 |
| therapy interruptedSignal | 43 | 16.5 | 12.3 | 613 |
| product use issueSignal | 60 | 8.8 | 6.9 | 408 |
| illnessSignal | 32 | 8.5 | 6.1 | 206 |
| product dose omission issueSignal | 83 | 7.7 | 6.3 | 487 |
| hospitalisationSignal | 42 | 7.5 | 5.6 | 232 |
| weight increasedSignal | 42 | 5.1 | 3.8 | 138 |
| weight decreasedSignal | 48 | 4.7 | 3.6 | 139 |
| drug ineffective | 93 | 1.9 | 1.6 | 44 |
| pain | 38 | 1.7 | 1.2 | 10 |
| fatigue | 43 | 1.5 | 1.1 | 7 |
| headache | 32 | 1.4 | 1.0 | 3 |
| off label use | 34 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.